Wegovy, Ozempic and Knee Joint Pain: Relief, and New Aches

Semaglutide — sold as Wegovy for weight management and Ozempic for type 2 diabetes — reduced knee osteoarthritis pain substantially more than placebo in a 68-week randomized trial, and the plausible mechanism is the weight that came off rather than any direct effect on cartilage. At the same time, many people starting a GLP-1 drug report new aches in the knees, hips, shoulders and back. Both things can be true. This page separates them: what the trial evidence supports, what the drug labels actually say about joint pain, and which mechanism most plausibly explains new soreness in someone losing weight fast.

What these drugs actually act on

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are injectable incretin drugs. They slow gastric emptying, blunt appetite signaling in the hypothalamus, and increase glucose-dependent insulin secretion. Those are metabolic actions, not joint actions, and no direct effect on human cartilage, synovium or subchondral bone has been demonstrated. Whatever these drugs do for an arthritic knee, the demonstrated route is indirect — through body mass, body composition, and the low-grade inflammatory state that comes with excess adipose tissue. That sets the ceiling on what to expect. A GLP-1 drug is not a joint drug; it is a metabolic drug whose downstream effects reach the joint.

The evidence that weight loss on semaglutide reduces knee arthritis pain

The strongest data come from STEP 9, a 68-week double-blind trial at 61 sites in 11 countries. It enrolled 407 adults with a BMI of 30 or higher and radiographically confirmed moderate knee osteoarthritis with at least moderate pain, randomized 2:1 to weekly semaglutide 2.4 mg or placebo. Both arms received counseling on physical activity and a reduced-calorie diet.¹

• Body weight fell 13.7% with semaglutide versus 3.2% with placebo.
• WOMAC pain scores (0–100, higher is worse; mean baseline 70.9) fell 41.7 points versus 27.5 points.
• SF-36 physical function improved 12.0 points versus 6.5 points.

Two things deserve attention. First, the placebo group improved a lot — 27.5 points — which is what diet counseling, activity counseling, regression to the mean and the placebo response together produce in a knee OA trial. The drug’s incremental advantage was roughly 14 points, not 42. Second, serious adverse events were similar between groups, but 6.7% of the semaglutide arm stopped treatment permanently for adverse events versus 3.0% on placebo, mostly gastrointestinal.¹

A 2025 network meta-analysis of 56 obesity-drug trials covering 60,307 patients listed semaglutide as the obesity agent with a demonstrated reduction in knee osteoarthritis pain.⁴ That reflects the same STEP 9 result rather than an independent replication of it. An independent osteoarthritis year-in-review called the STEP 9 result substantial, with a possible but unconfirmed disease-modifying effect operating through weight loss.⁹ That is the honest framing: symptom improvement is established; structural disease modification is not.

Why losing weight changes what a knee feels

Two mechanisms, both measured directly rather than assumed.

Mechanical. In 142 overweight and obese older adults with knee OA who underwent three-dimensional gait analysis, each 1 kg of body mass lost was associated with roughly a 40 N reduction in peak knee compressive force during walking — about a fourfold reduction in joint load per unit of weight.² Multiplied across thousands of steps a day, the cumulative unloading is not trivial.

Inflammatory. The IDEA trial randomized 454 adults with knee OA to intensive diet, exercise, or both for 18 months. Both diet-containing arms had lower plasma interleukin-6 than exercise alone, and the diet-alone arm had lower knee compressive force than exercise alone. Diet plus exercise produced the best pain and function scores of the three.³ Adipose tissue is metabolically active; reducing it lowers inflammatory signaling that sensitizes an already irritated joint.

Note the shape of that result. Diet did the unloading, but diet plus exercise did the most for pain. Weight loss without preserved muscle is the weaker strategy — which is where the second half of this question lives.

Does Wegovy cause joint pain or arthritis?

Start with the regulatory record, because it is checkable. The current FDA prescribing information for Wegovy lists no arthralgia, joint pain, osteoarthritis or myalgia — not in the clinical-trial adverse reactions table, and not in the postmarketing experience section. The same is true of the current Ozempic and Zepbound labels.⁷ Whatever joint pain people experience on these drugs, it has not met the bar for a labeled adverse reaction.

There is a widely cited joint-pain warning in diabetes medicine, but it belongs to a different drug class. DPP-4 inhibitors — sitagliptin, saxagliptin, linagliptin, alogliptin — carry a Warnings and Precautions section for “Severe and Disabling Arthralgia,” describing postmarketing reports with onset from one day to years after starting therapy, relief on discontinuation, and recurrence on rechallenge with the same or another DPP-4 inhibitor.⁸ These are oral tablets that raise your own GLP-1 levels indirectly. They are not GLP-1 agonists, and the two get conflated constantly.

Pharmacovigilance data draw the same line. A disproportionality analysis of 15,052 musculoskeletal adverse-event reports in the FDA Adverse Event Reporting System found no signal at the system-organ-class level for incretin drugs overall. Among specific reported terms, GLP-1 receptor agonists were associated with back pain and myalgia, tirzepatide with muscle atrophy — while the osteoarthritis and arthritis signals attached to DPP-4 inhibitors. Median time to onset for GLP-1 and tirzepatide reports was 30 days or less.⁶

Spontaneous reports cannot establish causation, and the population taking these drugs already has a high baseline prevalence of osteoarthritis — some of what gets reported would have happened anyway. But the pattern is informative: early muscle and soft-tissue complaints, rather than joint-specific ones.

The muscle problem is the most plausible explanation

A 2026 systematic review in Annals of Internal Medicine examined body composition across 35 randomized trials of liraglutide, semaglutide, tirzepatide or dulaglutide. The median share of total weight loss attributable to muscle-related indices was 28.3% (IQR 15.9–39.9%), and about two thirds of the incretin interventions exceeded the prespecified benchmark of roughly 25%. Critically, no study reported an objective physical function outcome — nobody measured whether these patients got weaker.⁵

This is the mechanism that fits the complaints. Muscle is not incidental to a knee: body composition — high fat mass combined with low lean mass — has been identified as a factor influencing osteoarthritis severity and physical function,⁹ and more thigh muscle mass tracks with lower knee osteoarthritis risk. Someone who drops 30 pounds in six months on a steep caloric deficit, without resistance training or adequate protein, has unloaded the joint mechanically while removing part of the muscular system that stabilizes and decelerates it. New aching in the knees, hips and low back a few weeks into treatment fits that trade, not a drug attacking cartilage. Suppressed appetite also thins protein, hydration and micronutrient intake at exactly the moment tissue is remodeling. Those are correctable problems.

If your joints hurt on a GLP-1 drug

• Get the joint examined. New pain in a single joint with swelling, redness, locking or night pain is not a body-composition story and needs a diagnosis.
• Count protein. Losing weight on a suppressed appetite without deliberate protein intake is how lean mass goes.
• Load the muscle. Resistance training is the standard countermeasure, and IDEA showed why it matters for pain specifically: adding exercise to diet beat diet alone on both pain and function.³
• Watch the size of the deficit, not just the scale. In a meta-analysis of resistance-training trials performed in an energy deficit, lean-mass gains were impaired relative to training without a deficit, and deficits beyond roughly 500 kcal a day prevented gains in lean mass — while strength gains were largely preserved.¹¹
• Check the rest of the list. If you also take a DPP-4 inhibitor, that class carries a labeled joint-pain warning.⁸

What weight loss will not fix

STEP 9 enrolled people with moderate radiographic knee OA. A knee with advanced structural damage, malalignment, meniscal pathology or bone-on-bone joint space loss does not become a normal knee at a lower body weight — it becomes a damaged knee carrying less load. That is real relief, and it is not reversal. Nothing in the trial data supports a claim that these drugs regenerate cartilage. When pain persists despite good metabolic progress, the question becomes what is generating the signal in that specific joint — a diagnostic question, not a weight question. Other drivers of persistent pain often coexist with a bad knee and get attributed to it by default.

If you are in the St. Louis area

Padda Institute evaluates knee osteoarthritis alongside the metabolic picture rather than separately, because the two interact. When conservative care and weight management leave a knee painful, options include genicular nerve blocks as a diagnostic step, genicular radiofrequency ablation to interrupt the sensory nerves supplying the joint capsule, and viscosupplementation. Dr. Gurpreet Singh Padda, MD, MBA, MHP practices at 4477 Woodson Rd, Suite 100, St. Louis, MO 63134 and at 12174 Natural Bridge Road, Suite 100, St. Louis, MO 63044. Call (314) 481-5000 or request an appointment.

Frequently asked questions

Is Wegovy approved to treat arthritis?

No. Knee osteoarthritis is not an approved indication and the FDA label carries no osteoarthritis claim.⁷ The pain benefit seen in STEP 9 is best understood as a downstream effect of weight loss, which is why it belongs in a metabolic and lifestyle medicine plan rather than in arthritis treatment.

Can Wegovy cause arthritis?

There is no evidence that it causes osteoarthritis or inflammatory arthritis, and neither arthralgia nor arthritis appears in the current Wegovy prescribing information.⁷ In FDA adverse-event reporting, arthritis signals cluster with DPP-4 inhibitors, a different class.⁶ New joint symptoms during rapid weight loss fit lean-mass loss and deconditioning better, which is why structured lifestyle medicine with resistance training belongs in the plan from the start.

How much weight loss does it take to notice a difference in the knee?

Joint load changes immediately and in proportion to body mass, so small losses register mechanically before they look impressive on a scale.² The trials that produced clear symptom improvement went well beyond small, though: mean weight loss was 13.7% in STEP 9 and 11.4% in the diet-plus-exercise arm of IDEA.^1,3 That is the reasoning behind pairing medical weight loss with joint-directed care.

Will the joint pain come back if I stop the medication?

In the STEP 1 trial extension, participants regained about two thirds of their lost weight in the year after semaglutide and lifestyle intervention were withdrawn, and most cardiometabolic improvements drifted back toward baseline.¹⁰ Because the joint benefit is a function of load and inflammation rather than a lasting change to the joint, symptoms tend to follow the weight. Regaining muscle is not automatic either. Plan the exit before you need it — see what to expect when stopping Ozempic.

Does tirzepatide (Mounjaro, Zepbound) do the same thing for knees?

Tirzepatide produces comparable or greater weight loss, but it has not been tested in a dedicated knee osteoarthritis trial the way semaglutide was, so the joint-specific evidence is not equivalent. In adverse-event reporting it carried a muscle-atrophy signal.⁶ For a comparison, see how Mounjaro compares to other diabetes weight-loss drugs.

What if my knee still hurts after I lose the weight?

Then the pain generator needs identifying rather than more weight loss. A diagnostic genicular nerve block establishes whether the sensory nerves supplying the joint capsule are carrying the signal, which determines whether genicular nerve ablation for knee osteoarthritis is reasonable. Escalating opioids is not the answer; the practice’s position is set out in its opioid stewardship policy.

Sources

1. Bliddal H, Bays H, Czernichow S, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024;391(17):1573-1583. PMID 39476339
2. Messier SP, Gutekunst DJ, Davis C, DeVita P. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum. 2005;52(7):2026-2032. PMID 15986358
3. Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA. 2013;310(12):1263-1273. PMID 24065013
4. McGowan B, Ciudin A, Baker JL, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med. 2025;31(10):3317-3329. PMID 41039116
5. Batsis JA, Gavras A, Gross DC, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review. Ann Intern Med. 2026;179(7):996-1013. PMID 41996180
6. Guo M, Chen S, Dong H, et al. Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(8):11975-11991. PMID 41748946
7. Novo Nordisk. WEGOVY (semaglutide) injection, solution — full prescribing information, label version 19, published June 30, 2026. DailyMed, U.S. National Library of Medicine. DailyMed. Novo Nordisk. OZEMPIC (semaglutide) injection, solution — full prescribing information, label version 20, published June 10, 2026. DailyMed. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, solution — full prescribing information, label version 38, published May 6, 2026. DailyMed
8. Merck Sharp & Dohme LLC. JANUVIA (sitagliptin) tablets — full prescribing information, section 5.6, Severe and Disabling Arthralgia. DailyMed, U.S. National Library of Medicine. Label version 71, published November 17, 2025. DailyMed
9. Dell’Isola A, Recenti F, Giardulli B, Lawford BJ, Kiadaliri A. Osteoarthritis year in review 2025: Epidemiology and therapy. Osteoarthritis Cartilage. 2025;33(11):1300-1306. PMID 40914550
10. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID 35441470
11. Murphy C, Koehler K. Energy deficiency impairs resistance training gains in lean mass but not strength: A meta-analysis and meta-regression. Scand J Med Sci Sports. 2022;32(1):125-137. PMID 34623696

Dr. Gurpreet Singh Padda, MD, MBA, MHP